2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide: structure in first source; a derivative of A77 1726, the active metabolite of the antirheumatic drug leflunomide, where the isoxazole ring has opened to become a nitrile and an alkyne [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 54686843 |
CHEMBL ID | 4754445 |
MeSH ID | M0269242 |
Synonym |
---|
manitimus |
fk-778 |
hmr-1715 |
x-920715 |
mna-715 |
fk 778 |
malononitrilamide 715 |
2-cyano-3-hydroxy-n-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide |
mna 715 |
x 920715 |
mna-x 920715 |
185915-33-7 |
malononitrilamide-715 |
2-hepten-6-ynamide, 2-cyano-3-hydroxy-n-(4-(trifluoromethyl)phenyl)-, (z)- |
2-cyano-3-hydroxy-n-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynoic acid |
unii-4b135rk2kl |
4b135rk2kl , |
(2z)-2-cyano-3-hydroxy-n-(4-(trifluoromethyl)phenyl)hept-2-en-6-ynamide |
2-hepten-6-ynamide, 2-cyano-3-hydroxy-n-(4-(trifluoromethyl)phenyl)- |
manitimus [inn] |
202057-76-9 |
hmr1715 |
(2z)-2-cyano-3-hydroxy-n-(4-(trifluoromethly)phenyl)-2-hepten-6-ynamide |
hmr-1715 [who-dd] |
DB06481 |
Q27259358 |
(z)-2-cyano-3-hydroxy-n-[4-(trifluoromethyl)phenyl]hept-2-en-6-ynamide |
BM162377 |
irelroqhiplasx-seyxrhqnsa-n |
CHEMBL4754445 |
AKOS040733665 |
Excerpt | Reference | Relevance |
---|---|---|
" A safe and effective immunosuppressive agent that does not predispose to viral infection is needed in transplantation." | ( Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. First, MR; Fitzsimmons, W; Guasch, A; Holman, J; Roy-Chaudhury, P; Woodle, ES, 2010) | 0.36 |
" Although the treatment with FK778 decreased BK viral load in this study, it was associated with a less favorable rejection profile and renal function and a higher incidence of serious adverse events compared with reduction of immunosuppression." | ( Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. First, MR; Fitzsimmons, W; Guasch, A; Holman, J; Roy-Chaudhury, P; Woodle, ES, 2010) | 0.36 |
Excerpt | Reference | Relevance |
---|---|---|
"In a double-blind manner, 149 patients were randomized to a 12-week treatment with FK778 in combination with tacrolimus (Tac) and corticosteroids (S)." | ( The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Chang, R; Charpentier, B; Grinyó, JM; Jurewicz, A; Klinger, M; Kreis, H; Mourad, G; Neuhaus, P; Paczek, L; Paul, LC; Rostaing, L; Short, C; Squifflet, JP; van Hooff, JP; Vanrenterghem, Y; Wlodarczyk, Z, 2004) | 0.32 |
"We evaluated the in vitro capacity of FK778, alone or in combination with other immunosuppressive drugs: Tacrolimus (TRL); Sirolimus (SRL), Everolimus (EVL), to inhibit clonal expansion of T-lymphocytes and expression of lymphocyte-activation surface antigens; secondly, we compared the immunosuppressive potential of FK778 combined with TRL, SRL and EVL with the same combinations using Mycophenolic acid (MPA) as antimetabolite." | ( Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens. Barceló, JJ; Brunet, M; Fortuna, V; Jiménez, O; Millán, O, ) | 0.13 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 36 (41.38) | 18.2507 |
2000's | 47 (54.02) | 29.6817 |
2010's | 4 (4.60) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (9.61) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (2.88%) | 5.53% |
Reviews | 6 (5.77%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 95 (91.35%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |